Rafael Holdings Q4 net loss narrows on lower costs

By Reuters News


Overview

  • US biotechnology firm's fiscal Q4 net loss narrowed year over year on lower administrative expenses

  • Fiscal Q4 revenue declined year over year

  • Quarterly research and development expenses were flat year over year


Outlook

  • Company has requested a rare pediatric disease priority review voucher with NDA submission


Result Drivers

  • ADMINISTRATIVE COSTS - Co said lower payroll, stock-based compensation and professional fees reduced administrative expenses

  • SETTLEMENT GAINS - Co cited gains from settlements of accounts payable and convertible notes payable as a factor in reduced annual net loss


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Loss attributab e to company

$9.20 mln

Q4 Operating Income

-$9.73 mln


Reuters Recommended Reads

  • Oct 28 - Viking Therapeutics posts bigger-than-expected Q3 loss as costs rise

  • Oct 27 - Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance

  • Oct 29 - Ligand Pharmaceuticals Q3 royalty revenue jumps 51%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.